No headlines found.
Globe Newswire (Thu, 16-Apr 9:00 AM ET)
Fate Therapeutics to Participate in Upcoming Second Quarter 2026 Conferences
Globe Newswire (Thu, 9-Apr 9:00 AM ET)
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Thu, 2-Apr 4:05 PM ET)
The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven't Noticed
Globe Newswire (Wed, 18-Mar 11:30 AM ET)
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Wed, 4-Mar 4:05 PM ET)
Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference
Globe Newswire (Tue, 3-Mar 4:05 PM ET)
Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
Globe Newswire (Thu, 26-Feb 9:00 AM ET)
Globe Newswire (Mon, 16-Feb 1:00 PM ET)
Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets
Globe Newswire (Fri, 23-Jan 12:56 PM ET)
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Fate Therapeutics trades on the NASDAQ stock market under the symbol FATE.
As of April 16, 2026, FATE stock price climbed to $1.35 with 593,228 million shares trading.
FATE has a beta of 1.66, meaning it tends to be more sensitive to market movements. FATE has a correlation of 0.07 to the broad based SPY ETF.
FATE has a market cap of $155.70 million. This is considered a Micro Cap stock.
Last quarter Fate Therapeutics reported $1 million in Revenue and -$.27 earnings per share. This beat revenue expectation by $50,116 and met earnings estimates .
In the last 3 years, FATE traded as high as $8.83 and as low as $.66.
The top ETF exchange traded funds that FATE belongs to (by Net Assets): VTI, IWM, VXF, IWN, SCHA.
FATE has underperformed the market in the last year with a return of +20.5%, while SPY returned +31.8%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in FATE shares. However, FATE has outperformed the market in the last 3 month and 2 week periods, returning +28.6% and +8.9%, while SPY returned +1.6% and +7.0%, respectively. This indicates FATE has been having a stronger performance recently.
FATE support price is $1.22 and resistance is $1.36 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that FATE shares will trade within this expected range on the day.
